Whitehawk Therapeutics awarded Chief Scientific Officer Dornan David 171,774 derivative securities in two code A transactions on September 15 at $0 per share. After the transactions, David owned 85,887 derivative securities, giving investors the reported post-transaction holding tied to the company’s disclosed award activity.

Key Highlights

  • The transactions were recorded on 15 September 2026 at $0 per share.
  • Dornan David owned 85,887 derivative securities after the transactions.
  • The transactions carried SEC transaction code A.

Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded 171,774 derivative securities across two transactions. Dornan David, the company’s chief scientific officer, received the awards.

The transactions carried SEC transaction code A. They were recorded on 15 September 2026 at $0 per share. The awards covered derivative securities of Whitehawk Therapeutics.

Reported Post-Transaction Position

Following the transactions, Dornan David owned 85,887 derivative securities. That figure represents the reported holding after the award activity. Whitehawk Therapeutics identified David as its chief scientific officer. Transaction code A denotes an award, grant, or other Acquisition from the company.